Drug-drug interaction with two different route of administration [Design Issues]

posted by Mr.Rao – India, 2022-07-21 13:24 (1059 d 15:50 ago) – Posting: # 23153
Views: 3,725

❝ I think the information provided is too little.


Dear Shah,


Information we received from sponsor:

Sponsor need to check their X-Drug for Idiopathic pulmonary fibrosis treatment along with nintedanib.

First, we will provide the nintedanib for 8 days and we will collect the PK sample and from days 9-16 we will provide both nintedanib and X-Drug and we will collect PK samples, from that sponsor need to check Drug-drug interactions.

Here X-Drug is inhaler and nintedanib is tab/cap.

So what is the procedure.

Thanks,
Rao


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
12 visitors (0 registered, 12 guests [including 11 identified bots]).
Forum time: 05:15 CEST (Europe/Vienna)

To call the statistician after the experiment is done
may be no more than asking him to perform a postmortem examination:
he may be able to say what the experiment died of.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5